Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley Fever in adults: an open-label, non-randomised, first-in-human phase 1 clinical trial

BACKGROUND: Rift Valley Fever (RVF) is a viral epidemic illness prevalent in Africa that can be fatal or result in debilitating sequelae in humans. No vaccines are available for human use. We evaluated the safety and immunogenicity of a non-replicating simian adenovirus (ChAdOx1)-vectored RVF vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkin, Daniel, Wright, Daniel, Folegatti, Pedro M., Platt, Abigail, Poulton, Ian, Lawrie, Alison, Tran, Nguyen, Boyd, Amy, Turner, Cheryl, Gitonga, John N., Karanja, Henry K., Mugo, Daisy, Ewer, Katie J., Bowden, Thomas A., Gilbert, Sarah C., Charleston, Bryan, Kaleebu, Pontiano, Hill, Adrian V. S., Warimwe, George M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614834/
https://www.ncbi.nlm.nih.gov/pubmed/37060917
http://dx.doi.org/10.1016/S1473-3099(23)00068-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614834/
https://www.ncbi.nlm.nih.gov/pubmed/37060917
http://dx.doi.org/10.1016/S1473-3099(23)00068-3

Ejemplares similares